Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCS005
- Development stage
- Preclinical
- Lead developer
- Glen Clova Scientific
- Modality
- Vaccines & Immunotherapeutics
01
Overview
GCS005 is an active biologic drug candidate in discovery-stage development by Glen Clova Scientific for the treatment of chronic inflammatory, autoimmune, and immuno-dermatological conditions. Developed using the company's proprietary virus-like particle (VLP) platform, GCS005 is designed as a therapeutic vaccine that displays target antigens on the surface of VLPs. This approach stimulates the patient's immune system to produce neutralizing antibodies against specific disease-driving proteins, offering a highly targeted therapeutic effect with potentially reduced dosing frequency (such as once or twice annually) compared to traditional biologics.
02
Targets
IL-13 (Interleukin-13)
Beyond the preview
Go deeper on GCS005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCS005.